Skip to main content

Laura Jean Havrilesky, MD

Laura Havirlesky, MD
Professor of Obstetrics and Gynecology
Campus Mail: 25172 Morris Bldg, Durham, NC 27710
Phone: (919) 684-0188
Email: havri001@mc.duke.edu

I am interested in using health economic models to inform decisions related to gynecologic cancers. Specific models have addressed the decision to administer intraperitoneal chemotherapy for newly diagnosed advanced ovarian cancer following optimal cytoreduction, the choice of chemotherapy regimen for recurrent platinum-sensitive ovarian cancer, and the exploration of screening strategies for ovarian cancer. The ovarian cancer screening model examines the effects of test cost, sensitivity, specificity, and screen frequency on ovarian cancer mortality, the lifetime false positive rate of testing, the positive predictive value of the test, and its cost effectiveness. This type of model is potentially useful in informing the design trials of novel screening tests for ovarian cancer. I am also conducting a prospective study to quantify the effects of screening for, diagnosis of, and treatment for ovarian cancer on the quality of life of women.

Education and Training

  • Residency, Obstetrics And Gynecology, Duke University, 1995 - 1999
  • M.D., Duke University, 1995

Research

I am interested in using health economic models to inform decisions related to gynecologic cancers. Specific models have addressed the decision to administer intraperitoneal chemotherapy for newly diagnosed advanced ovarian cancer following optimal cytoreduction, the choice of chemotherapy regimen for recurrent platinum-sensitive ovarian cancer, and the exploration of screening strategies for ovarian cancer.

The ovarian cancer screening model examines the effects of test cost, sensitivity, specificity, and screen frequency on ovarian cancer mortality, the lifetime false positive rate of testing, the positive predictive value of the test, and its cost effectiveness. This type of model is potentially useful in informing the design trials of novel screening tests for ovarian cancer. I am also conducting a prospective study to quantify the effects of screening for, diagnosis of, and treatment for ovarian cancer on the quality of life of women. 

Publications

Fleming, ND, Havrilesky, LJ, Valea, FA, Allen, TK, Broadwater, G, Bland, A, and Habib, AS. "Analgesic and antiemetic needs following minimally invasive vs open staging for endometrial cancer." Am J Obstet Gynecol 204, no. 1 (January 2011): 65.e1-65.e6.

Full Text

Morgan, RJ, Alvarez, RD, Armstrong, DK, Boston, B, Burger, RA, Chen, L-M, Copeland, L, Crispens, MA, Gershenson, D, Gray, HJ, Grigsby, PW, Hakam, A, Havrilesky, LJ, Johnston, C, Lele, S, Matulonis, UA, O'Malley, DM, Penson, RT, Remmenga, SW, Sabbatini, P, Schilder, RJ, Schink, JC, Teng, N, Werner, TL, and National Comprehensive Cancer Network, . "Epithelial ovarian cancer." Journal of the National Comprehensive Cancer Network : Jnccn 9, no. 1 (January 2011): 82-113.

Full Text

Wallace, AH, Havrilesky, LJ, Valea, FA, Barnett, JC, Berchuck, A, and Myers, ER. "Projecting the need for gynecologic oncologists for the next 40 years." Obstet Gynecol 116, no. 6 (December 2010): 1366-1372.

Full Text

Barnett, JC, Judd, JP, Wu, JM, Scales, CD, Myers, ER, and Havrilesky, LJ. "Cost comparison among robotic, laparoscopic, and open hysterectomy for endometrial cancer." Obstet Gynecol 116, no. 3 (September 2010): 685-693.

Full Text

Havrilesky, LJ, Krivak, TC, Mucenski, JW, and Myers, ER. "Impact of a chemoresponse assay on treatment costs for recurrent ovarian cancer." Am J Obstet Gynecol 203, no. 2 (August 2010): 160.e1-160.e7.

Full Text

Judd, JP, Siddiqui, NY, Barnett, JC, Visco, AG, Havrilesky, LJ, and Wu, JM. "Cost-minimization analysis of robotic-assisted, laparoscopic, and abdominal sacrocolpopexy." J Minim Invasive Gynecol 17, no. 4 (July 2010): 493-499.

Full Text

Jewell, EL, Darcy, KM, Hutson, A, Lee, PS, Havrilesky, LJ, Grace, LA, Berchuck, A, and Secord, AA. "Association between the N-terminally truncated (DeltaN) p63alpha (DeltaNp63alpha) isoform and debulking status, VEGF expression and progression-free survival in previously untreated, advanced stage epithelial ovarian cancer: A Gynecologic Oncology Group study." Gynecologic Oncology 115, no. 3 (December 2009): 424-429.

Full Text

Fader, AN, Starks, D, Gehrig, PA, Secord, AA, Frasure, HE, O'Malley, DM, Tuller, ER, Rose, PG, Havrilesky, LJ, Moore, KN, Huh, WK, Axtell, AE, Kelley, JL, Zanotti, KM, and UPSC Consortium, . "An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC)." Gynecol Oncol 115, no. 2 (November 2009): 244-248.

Full Text

Lee, PS, Bland, A, Valea, FA, Havrilesky, LJ, Berchuck, A, and Secord, AA. "Robotic-assisted laparoscopic gynecologic procedures in a fellowship training program." Jsls : Journal of the Society of Laparoendoscopic Surgeons 13, no. 4 (October 2009): 467-472.

Full Text

Secord, AA, Havrilesky, LJ, O'Malley, DM, Bae-Jump, V, Fleming, ND, Broadwater, G, Cohn, DE, and Gehrig, PA. "A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer." Gynecologic Oncology 114, no. 3 (September 2009): 442-447.

Full Text

Pages